Baseline characteristics of the three AS cohorts (totalling 692 patients) in whom the original BASDAI was compared with the mini-BASDAI
| Baseline parameters | (1) GESPIC cohort* | (2) TNFα trial population† | (3) NSAID trial population‡ |
| No of patients (N) | 228 | 91 | 373 |
| % Male | 64.9% | 69.2% | 69.2% |
| % HLA-B27-positive | 83.8% | 88.9% | NA |
| Mean age, in years (SD) | 35.4 (10.2) | 37.8 (8.4) | 43.9 (12.4) |
| Mean disease duration, in years (SD) | 5.3 (2.7) | 14.2 (8.3) | NA |
| BASDAI (0–10), mean (SD) | 3.94 (2.10) | 6.51 (1.23) | 4.66 (1.60) |
| Mini-BASDAI (0–10), mean (SD) | 4.72 (2.12) | 7.00 (1.24) | 5.54 (1.64) |
| BASFI (0–10), mean (SD) | 3.20 (2.50) | 5.42 (2.01) | 4.27 (2.22) |
| Patient global (0–10), mean (SD) | 5.04 (2.55) | 7.25 (1.75) | 6.23 (1.76) |
| % of patients without peripheral manifestation (“P−” group)§ | 70.6% | 39.6% | 100%‡ |
*German Spondyloarthritis Inception Cohort (GESPIC), 228 ankylosing spondylitis (AS) patients seen cross-sectionally at baseline in 13 centres in Germany.22
†Tumour necrosis factor alpha (TNFα) trial population, 91 patients who were treated with infliximab or etanercept in the setting of clinical trials.23 24
‡Non-steroidal anti-inflammatory drug (NSAID) trial population, 373 AS patients who were treated with either celecoxib (200 mg a day or 200 mg twice a day) or diclofenac 75 mg twice a day for 12 weeks in the setting of a double-blind, randomised controlled trial in 46 German study centres. Peripheral arthritis was an exclusion criterion.25
§“P−”, subgroup of patients without peripheral involvement.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; mini-BASDAI, BASDAI without Q3arthritis and Q4enthesitis; BASFI, Bath Ankylosing Spondylitis Functional Index; NA, not assessed.